tinnitus, never previously warned, as soon as i received the third dose of anticovid vaccine, which increased over the days and persists despite treatment.; this case was received (reference number: it-minisal02-841268) on 25-feb-2022 and was forwarded to moderna on 25-feb-2022. this regulatory authority case was reported by a consumer and describes the occurrence of tinnitus (tinnitus, never previously warned, as soon as i received the third dose of anticovid vaccine, which increased over the days and persists despite treatment.) in a 59-year-old female patient who received mrna-1273 (spikevax) (batch no. 214023) for covid-19 vaccination. no medical history information was reported. on 10-oct-2021, the patient received dose of mrna-1273 (spikevax) (intravenous) 50 microgram. on 14-dec-2021, after starting mrna-1273 (spikevax), the patient experienced tinnitus (tinnitus, never previously warned, as soon as i received the third dose of anticovid vaccine, which increased over the days and persists despite treatment.) (seriousness criterion disability). at the time of the report, tinnitus (tinnitus, never previously warned, as soon as i received the third dose of anticovid vaccine, which increased over the days and persists despite treatment.) had not resolved. no concomitant product was provided by the reporter. no treatment medication was provided. company comment: this literature case concerns a 59-year-old female with no medical who experienced the serious (disability), unexpected event of tinnitus 66 days after an unknown dose of mrna-1273. treatment and testing not reported. the outcome is not resolved. the risk-benefit relationship of mrna-1273 vaccine is not affected by this report.; reporter's comments: tinnitus when administering dose booster anticovid vaccine; sender's comments: this literature case concerns a 59-year-old female with no medical who experienced the serious (disability), unexpected event of tinnitus 66 days after an unknown dose of mrna-1273. treatment and testing not reported. the outcome is not resolved. the risk-benefit relationship of mrna-1273 vaccine is not affected by this report